Response to 'Re. Benefits of Remote Ischemic Preconditioning in Vascular Surgery' The authors make a good point: discrepancy between animal and clinical data is multifactorial, and the factors they cite are likely to be an influence.
Response to Letter to the Editor: 'Re: Endograft Limb Occlusion in EVAR: Iliac Tortuosity Quantified by Three Different Indices on the Basis of Pre-operative CTA' We thank the group for their insightful comments and the opportunity to clarify a number of points from our work on endograft limb occlusion.
In our series to determine a cut-off value of common iliac artery tortuosity index (CAI) for high-risk patients, we constructed a receiver operating characteristic (ROC) curve. The area under curve was 0.72 (95% CI 0.55e0.88) with a best cut-off value of 1.26. With CAI 1.26, the positive predictive value was 67% and the negative predictive value was 65%. The sensitivity and specificity were 59% and 85%, respectively. The relative risk for limb occlusion was 2.8.
Our article is a cohort study, so we do acknowledge the limitation of the chosen control group. Four patients in the control group had double iliac sign (DIS), and two of these had primary adjunctive stenting performed. In our series we simply state the observation that two other patients with DIS had their z-stent part of the graft limbs placed directly within the most tortuous part of the vessel, therefore having the part of the graft limb with the most radial force where it was needed. We acknowledge this may simply be pure speculation.
During the extended decade period 2000e2010, we used only the Zenith flex (Cook Inc, Bloomington, IN, USA) limbs. The incidence of limb occlusions was equally distributed in the time period.
We hope that other centres will review and publish their survival results to provide further information, and we hope this will provide a more robust answer to some of the questions that have been raised. We read with interest the review article of Twine et al. 1 In recent years several articles have addressed this topic and reported various results with regard to the extent of organ protection. In our opinion, it is to be expected that the clinical application of this technique will encounter similar drawbacks as we have witnessed with the concept of ischemic and pharmacological preconditioning. Indeed, despite the promising data from experimental studies, the implementation of preconditioning strategies in clinical practice was disappointing. This apparent discrepancy between experimental and clinical data is multifactorial but central in this is the fact that a cardiac or vascular patient with his associated pathology can by no means be compared to an experimentaldmostly healthydanimal model. Associated pathology such as for instance diabetes and concurrent medication have been shown to interfere with the mechanisms of preconditioning. As such, the beneficial effects of these strategies may very well be blocked by these factors.
Another key element that is frequently overlooked is the concurrent influence of anesthetic agents. Volatile anesthetics have a pharmacological preconditioning effect, and, specifically in coronary surgery, it has been shown that the use of such agents was associated with less postoperative myocardial damage and a better preservation of myocardial function. 2, 3 Interestingly, when a remote ischemic preconditioning protocol was applied on top of a volatile anesthetic regimen, no additional protection was observed. 4 We therefore suggest that future studies and reports take this variable into account. It is very well possible that the absence of effect in certain remote ischemic preconditioning protocols may be related to the fact that the strategy was applied on top of a volatile anesthetic based anesthesia. The routine practice of thrombolysis in ischemic stroke patients is derived from well-conducted, randomized controlled trials (RCTs), 1 which are the foundation of evidence-based medicine (EBM). Those studies have proved themselves extremely useful for stroke patients, helping so many people to have better outcomes after their strokes. Currently, intravenous thrombolytic therapy is recommended within 4.5 hours of the onset of symptoms in patients with acute ischemic stroke, once intracranial bleeding has been excluded by computed tomography. 2, 3 The exact identification of the site of occlusion causing the ischemia or, more in general, of the exact cause of stroke, is not considered mandatory before starting fibrinolytic therapy, as none of the RCTs studying the effect of rt-PA in ischemic stroke patients was designed to address the differential effects on different types or causes of ischemic strokes by using vascular imaging. 4, 5 Hence, a carotid axis scan is not routinely performed until the rt-PA administration has been completed. Unfortunately, it is likely that not all the patients receiving intravenous systemic rt-PA will gain the greatest efficacy and benefit from fibrinolytic therapy, and this is probably related to the lack of a careful diagnosis of the
